# US 2017/0283783 A1 · Human beta-adrenergic receptor kinase polypeptide and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283783 A1
- Document ID: US20170283783A1
- Status: Published application
- Kind: A1
- Application number: 15/624,487
- Filed: 2017-06-15
- Published: 2017-10-05
- Earliest claimed: 2003-04-30
- Assignees: Incyte Corporation
- Applicants: Incyte Corporation
- Inventors: Vicki S. Kaulback; Reena Khare; Thomas W. Richardson; Joseph P. Marquis; Anita Swarnakar; April J. A. Hafalia; Shanya D. Becha; Narinder K. Chawla-Walia; Mariah R. Baughn; Soo Yeun Lee; Uyen K. Tran; Henry Yue; Danniel B. Nguyen; Michael B. Thorton; Rajagopal Gururajan; Ameena R. Gandhi; Yan Lu; Monique G. Yao; Joana X. Li; Wen Luo; Ernestine A. Lee; Craig H. Ison; Amy D. Wilson; Pei Jin; Ian J. Forsythe
- Web page: https://patentgrep.com/patent/US20170283783A1

## CPC

- C12N 9/16: acting on ester bonds (3.1)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- G01N 33/573: for enzymes or isoenzymes
- G01N 2800/70: Mechanisms involved in disease identification (G01N2800/02 - G01N2800/44 take precedence)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of screening a compound for effectiveness as an agonist of a polypeptide, the method comprising:
a) contacting a sample comprising the polypeptide with a compound, and
b) detecting agonist activity in the sample,
wherein the polypeptide is selected from the group consisting of:
(i) a polypeptide comprising an amino acid sequence of SEQ ID NO:13;
(ii) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:13;
(iii) a polypeptide comprising a naturally occurring amino acid sequence at least 91% identical to the amino acid sequence of SEQ ID NO:13;
(iv) a polypeptide comprising a naturally occurring amino acid sequence at least 93% identical to the amino acid sequence of SEQ ID NO:13,
(v) a polypeptide comprising a naturally occurring amino acid sequence at least 94% identical to an amino acid sequence of SEQ ID NO:13;
(vi) a polypeptide comprising a naturally occurring amino acid sequence at least 95% identical to an amino acid sequence of SEQ ID NO:13;
(vii) a polypeptide comprising a naturally occurring amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:13;
(viii) a polypeptide comprising a naturally occurring amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:13;
(ix) a polypeptide comprising a naturally occurring amino acid sequence at least 98% identical to an amino acid sequence of SEQ ID NO:13;
(x) a polypeptide comprising a naturally occurring amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:13;
(xi) a polypeptide consisting essentially of a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:13;
(xii) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:13; and
(xiii) an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:13.

### Claim at position 3

-22. (canceled)

### Claim 23

A method of screening a compound for effectiveness as an antagonist of a polypeptide, the method comprising:
(a) contacting a sample comprising the polypeptide with a compound, and
(b) detecting antagonist activity in the sample,
wherein the polypeptide is selected from the group consisting of:
(i) a polypeptide comprising an amino acid sequence of SEQ ID NO:13;
(ii) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:13;
(iii) a polypeptide comprising a naturally occurring amino acid sequence at least 91% identical to the amino acid sequence of SEQ ID NO:13;
(iv) a polypeptide comprising a naturally occurring amino acid sequence at least 93% identical to the amino acid sequence of SEQ ID NO:13,
(v) a polypeptide comprising a naturally occurring amino acid sequence at least 94% identical to an amino acid sequence of SEQ ID NO:13;
(vi) a polypeptide comprising a naturally occurring amino acid sequence at least 95% identical to an amino acid sequence of SEQ ID NO:13;
(vii) a polypeptide comprising a naturally occurring amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:13;
(viii) a polypeptide comprising a naturally occurring amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:13;
(ix) a polypeptide comprising a naturally occurring amino acid sequence at least 98% identical to an amino acid sequence of SEQ ID NO:13;
(x) a polypeptide comprising a naturally occurring amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:13;
(xi) a polypeptide consisting essentially of a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:13;
(xii) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:13; and
(xiii) an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:13.

### Claim at position 5

-25. (canceled)

### Claim 26

A method of screening for a compound that specifically binds to a polypeptide, the method comprising:
(a) combining the polypeptide with at least one test compound under suitable conditions, and
(b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide,
wherein the polypeptide is selected from the group consisting of:
(i) a polypeptide comprising an amino acid sequence of SEQ ID NO:13;
(ii) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:13;
(iii) a polypeptide comprising a naturally occurring amino acid sequence at least 91% identical to the amino acid sequence of SEQ ID NO:13;
(iv) a polypeptide comprising a naturally occurring amino acid sequence at least 93% identical to the amino acid sequence of SEQ ID NO:13,
(v) a polypeptide comprising a naturally occurring amino acid sequence at least 94% identical to an amino acid sequence of SEQ ID NO:13;
(vi) a polypeptide comprising a naturally occurring amino acid sequence at least 95% identical to an amino acid sequence of SEQ ID NO:13;
(vii) a polypeptide comprising a naturally occurring amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:13;
(viii) a polypeptide comprising a naturally occurring amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:13;
(ix) a polypeptide comprising a naturally occurring amino acid sequence at least 98% identical to an amino acid sequence of SEQ ID NO:13;
(x) a polypeptide comprising a naturally occurring amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:13;
(xi) a polypeptide consisting essentially of a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:13;
(xii) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:13; and
(xiii) an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:13.

### Claim 27

A method of screening for a compound that modulates the activity of a polypeptide, the method comprising:
(a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide,
(b) assessing the activity of the polypeptide in the presence of the test compound, and
(c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide,
wherein the polypeptide is selected from the group consisting of:
(i) a polypeptide comprising an amino acid sequence of SEQ ID NO:13;
(ii) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:13;
(iii) a polypeptide comprising a naturally occurring amino acid sequence at least 91% identical to the amino acid sequence of SEQ ID NO:13;
(iv) a polypeptide comprising a naturally occurring amino acid sequence at least 93% identical to the amino acid sequence of SEQ ID NO:13,
(v) a polypeptide comprising a naturally occurring amino acid sequence at least 94% identical to an amino acid sequence of SEQ ID NO:13;
(vi) a polypeptide comprising a naturally occurring amino acid sequence at least 95% identical to an amino acid sequence of SEQ ID NO:13;
(vii) a polypeptide comprising a naturally occurring amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:13;
(viii) a polypeptide comprising a naturally occurring amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:13;
(ix) a polypeptide comprising a naturally occurring amino acid sequence at least 98% identical to an amino acid sequence of SEQ ID NO:13;
(x) a polypeptide comprising a naturally occurring amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:13;
(xi) a polypeptide consisting essentially of a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:13;
(xii) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:13; and
(xiii) an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:13.

### Claim at position 8

28-141. (canceled)

### Claim 142 (depends on 20)

The method of claim 20, wherein the polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 13.

### Claim 143 (depends on 20)

The method of claim 20, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 13.

### Claim 144 (depends on 20)

The method of claim 20, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 13.

### Claim 144 (depends on 20)

The method of claim 20, wherein the compound is an antibody.

### Claim 145 (depends on 23)

The method of claim 23, wherein the polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 13.

### Claim 146 (depends on 23)

The method of claim 23, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 13.

### Claim 147 (depends on 23)

The method of claim 23, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 13.

### Claim 148 (depends on 23)

The method of claim 23, wherein the compound is an antibody.

### Claim 149 (depends on 26)

The method of claim 26, wherein the polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 13.

### Claim 150 (depends on 26)

The method of claim 26, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 13.

### Claim 151 (depends on 26)

The method of claim 26, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 13.

### Claim 152 (depends on 26)

The method of claim 26, wherein the compound is an antibody.

### Claim 153 (depends on 27)

The method of claim 27, wherein the polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 13.

### Claim 154 (depends on 27)

The method of claim 27, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 13.

### Claim 155 (depends on 27)

The method of claim 27, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 13.

### Claim 156 (depends on 27)

The method of claim 27, wherein the compound is an antibody.
